Suppression of CASC2 expression can significantly attenuate cisplatin's inhibition of cervical cancer cell proliferation and increase the median lethal dose (IC50), while overexpression can enhance cisplatin's inhibition of cervical cancer cell proliferation and decrease the IC50 value. This evidence concerns the gene CASC2 and cervical carcinoma.